Black DM, Cummings SR, Karpf DB et al. 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535–1541.PubMedCrossRef
Chesnut CH, Silverman S, Andriano K et al. 2000 A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 109:267–276.PubMedCrossRef
Cummings SR, Black DM, Thompson DE, et al. 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures JAMA 280: 2077–2082.PubMedCrossRef
Ettinger B, Black DM, Mitlak BH et al. 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 282:637–645.PubMedCrossRef
Harris ST, Watts NB, Genant HK et al. 1999 Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis. JAMA 282:1344–1352.PubMedCrossRef
Reginster JY, Minne HW, Sorensen OH et al. 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83–91.PubMedCrossRef
Wasnich RD, 2000 Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85:1–6.CrossRef
Cummings SR, Karpf DB, Harris F et al. 2002 Improvement in spine bone density and reduction in risk of vertebral fracture during treatment with antiresorptive drugs. Am J Med 112:281–289.PubMedCrossRef
Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD 2002. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J. Bone Miner Res 17:1–10.PubMedCrossRef
Sorenson O, Kaufman JM, Wenderoth D, Chines A. 2003 Sustained effect of risedronate: a 7-year study in postmenopausal women, 9th Annual Meeting of the International Society for Clinical Densitometry. Abstract 43 K.
Miller PD, 2005 Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction. Curr Osteo Rep 3:103–110.
Strewler GJ, 2001 Physiologic actions of PTH and PTHrP: I. Skeletal actions. In: Bilezikian JP, Marcus R, Levine MA (eds) The Parathyroids: Basic and Clinical Concepts. Academic New York, pp. 213–226.
Bringhurst FR, 2001 Physiologic actions of PTH and PTHRP: II. Renal actions In: Bilezikian JP, Marcus R, Levine MA (eds) The Parathyroids: Basic and Clinical Concepts. Academic, New York, pp. 227–244.
Clemens TL, Broadus AE. 2001 Physiologic actions of PTH and PTHrP: IV. Vascular, cardiovascular, and neurologic actions. In: Bilezikian JP, Marcus R, Levine MA (eds) The Parathyroids: Basic and Clinical Concepts. Academic, New York, pp. 261–274.
Wysolmerski JJ, Stewart AF, Martin JT, 2001 Physiologic actions of PTH and PTHrP: V Epidermal, mammary, reproductive, and pancreatic tissues. In: Bilezikian JP, Marcus R, Levine MA (eds) The Parathyroids: Basic and Clinical Concepts. Academic New York, pp. 275–291.
Kronenberg HM, Binghurst FR, Segre GV, Potts JT, 2001 Parathyroid hormone biosynthesis and metabolism In: Bilezikian JP, Marcus R, Levine MA (eds) The Parathyroids: Basic and Clinical Concepts. Academic New York, pp. 17–30.
Miller PD, Bilezikian JP, Deal C, Harris ST, 2004 Clinical use of teriparatide in the real world: initial insights. Endocr Prac 10:139–148.
Hodsman AB, Bauer DC, Dempster DW, et al. 2005 Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26:688–703.PubMedCrossRef
Lindsay R, Nieves J, Formica C et al. 1997 Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550–555.PubMedCrossRef
Hodsman AB, Fraher LJ, Watson PH et al. 1997 A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 82:620–628.PubMedCrossRef
Lane NE, Sanchez S, Modin GW, Genant HK, Pierini A, Arnaud CD, 1998 Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. J Clin Invest 102:1627–1633.PubMed
Roe EB, Sanchez SD, del Puerto GA, Pierini E, Cann CE, Arnaud CD. 1999 Parathyroid hormonel 1–34 [hPTH(1–34)] and estrogen produce dramatic bone density increases in postmenopausal osteoporosis—results from a placebo-controlled randomized trial. J Bone Miner Res 14(Suppl 1): S137.
Cosman F, Nieves J, Woelfert L et al. 2001. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 16: 925–931.PubMedCrossRef
Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. 2000 Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 15: 944–951PubMedCrossRef
Wagman RB, Marcus R, Mutlak, BH. 2005. Treatment with parathyroid hormone. In: Drug Therapy for Osteoporosis, (M. Kleerekoper, ed.) Taylor & Francis, New York, pp. 91–112
Neer RM, Arnaud CD, Zanchetta JR et al. 2001 Effect of density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441.PubMedCrossRef
Vahle JL, Sato M, Long GG et al. 2002 Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety. Toxicol Path 30:312–321.CrossRef
Vahle JL, Long GG, Ma YL, Sato M. 2004 Bone neoplasms in F344 rats given teriparatide [rhPTH (1–34)] are dependent on duration of treatment and dose. Toxicol Path 32: 426–438.CrossRef
Pohl, G.; Wang, J, Scheele, WH. 2003 Effect of duration of teriparatide therapy on nonvertebral fracture risk. Arthritis Rheum 48(Suppl 9):S234.
Lindsay R, Scheele WH, Neer R et al. 2004 Sustained vertebral fracture risk reduction after withdrawal of teriparatide [recombinant human parathyroid hormone (1–34)] in postmenopausal women with osteoporosis. Arch Intern Med 164:2024–2030.PubMedCrossRef
Prince RL, Sipos AA, Hossain A et al. 2005 Sustained non-vertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 20: 1507–1513.PubMedCrossRef
Greenspan SL, Bone HG, Macciott TB et al. 2005 Preventing the first vertebral fracture in postmenopausal women with low bone mass using PTH (1–84): results from the TOP study. J Bone Miner Res 20(Suppl 1):S56
Hui SL, Slemenda CW, Johnston CC Jr. 1988 Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 81:1804–1809.PubMedCrossRef
Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B, 2001 Ten year probabilities of osteoporosis fracture according to BMD and diagnostic thresholds. Osteopor Int 12:989–995.CrossRef
FORTEO product labeling. Eli Lilly and Company, 2002, 2004.
Orwoll ES, Scheele WH, Paul S et al. 2003. The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9–17.PubMedCrossRef
Kurland ES, Cosman F, McMahan DJ, Rosen CJ, Lindsay R, Bilezikian JP, 2000. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85: 3069–3076.PubMedCrossRef
McClung MR, San Martin J, Miller PD et al. 2005 Opposite bone remodelling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165: 1762–1768.PubMedCrossRef
Chen P, Satterwhite JH, Licata AA et al. 2005 Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Mineral Res 20: 962–970.CrossRef
Chen P, Miller PD, Delmas PD, Misurski DA, Krege JK. 2005 Change in lumbar spine (BMD) and vertebral fracture risk reduction in teriparatide-treated women with osteoporosis. J Bone Miner Res postmenopausal: 1985–1990.
Deal C, Omizo M, Schwartz EN et al. 2005. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results form a 6-month double blind placebo-controlled trial. J Bone Miner Res 20:905–911.CrossRef
Rittmaster RS, Bolognese M, Ettinger MP et al. 2000 Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85:2129–2134.PubMedCrossRef
Black DM, Greenspan SL, Ensrud KE et al. 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207–1215.PubMedCrossRef
Black DM, Bilezikian JP, Ensrud KE et al. 2005 One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med 353:555–565.PubMedCrossRef
Kurland ES, Heller SL, Diamond B, McMahon DJ, Cosman F, Bilezikian JP. 2004 The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone (1–34)]. Osteoporos Int 15:992–997.PubMedCrossRef
Krege J, Heathman M, Reginster J, Satterwhite J, 2003 Increases in serum-terminal propertide of type I collagen with teriparatide treatment predict increases in lumbar spine bone density. Program and Abstracts The Endocrine Society's 85th Annual Meetings, Philadelphia, PA, USA, June 19–22, 2003.
Ettinger B, San Martin J, Crans G, Imre Pavo. 2004 Response of markers of bone turnover and bone density to teriparatide in postmenopausal women previously treated with an antiresorptive drug. J Bone Miner Res 19: 745–751.PubMedCrossRef
Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R. 2005 Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 353:566–575.PubMedCrossRef
Delmas PD, Licata AA, Crans GG et al. 2004 Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. J Bone Miner Res 19(Suppl 1): S44.
Dempster DW, Cosman F, Kurland AS et al. 2001 Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 16: 1846–1853.PubMedCrossRef
Jiang Y, Zhao J, Mitlak BH, Wang O, Genant HK, Eriksen EF. 2003 Recombinant Human Parathyroid hormone (1–34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932–1941.PubMedCrossRef
Arlot M, Meunier PJ, Boivin G et al. 2005 Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 20:1244–1253.PubMedCrossRef
Recker RR, Bare SP, Miller MA, Newman MK, Fox J. 2004 Treatment of osteoporotic women with parathyroid hormone 1–84 for 18 months improves cancellous bone formation and structure: a bone biopsy study. J Bone Miner Res (1 Suppl):S97.
Dempster DW, Moreau IA, Varela A et al. 2005 Treatment of postmenopausal osteoporotic women with parathyroid hormone 1–84 for 18 months improves trabecular bone architecture: a study of iliac crest biopsies using microcomputer tomography. J. Bone Miner Res (1 Suppl):S98.
Wilker CE, Jolette J, Smith SY et al. 2004 A No observable carcinogenic effect dose level identified in Fischer 344 rats following daily treatment with PTH (1–84) for 2 years: role of the c-terminal PTH receptor? J Bone Miner Res 19(Suppl 1):S98.
Tashjian AH, Chabner BA. 2002 Commentary on clinical safety of recombinant human parathyroid hormone 1–34 in the treatment of osteoporosis in men and postmenopausal women. J Bone Miner Res 17:1151–1161.PubMedCrossRef
Tashijan AH, Gagel RF. 2005 Teriparatide (human parathyroid hormone 1–34): two and a half years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res, in press.
Hodsman AB, Kisiel M, Adachi JD, Fraher LJ, Watson PH. 2000 Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1–34) therapy in women with severe osteoporosis. Bone 27:311–318.PubMedCrossRef
Melnick KA, Heathman M, O'Brien G, Gaich G, Satterwhite J. 2000 Evaluation of LY333334 [Recombinant human parathyroid hormone (1–34) treatment on total lumbar spine and femoral neck bone mineral density in postmenopausal osteoporotic women. AAPS Pharm Sci 2:abstract 586.
Miller PD, Hochberg MC, Wehren LE, Ross PD, Wasnich RD. 2005 How useful are measures of BMD and bone turnover? Curr Med Res Opin 21:545–553.PubMedCrossRef
Zanchetta JR, Bogado CE, Ferretti JL et al. 2003 Effects of teriparatide [recombinant human parathyroid hormone (1–34) on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 18:539–543.PubMedCrossRef